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ABSTRACT
Cytochrome P450 (P450) is a superfamily of enzymes which mediates metab-
olism of xenobiotics including drugs. Alprazolam, an anti-anxiety agent, is
metabolized in rat and human liver by P4503A1 and P4503A4 respectively,
to 4-hydroxy alprazolam (4-OHALP, pharmacologically less active) and -
hydroxy alprazolam (-OHALP, pharmacologically more active). We exam-
ined P450 mediated metabolism of alprazolam by rat and human brain
microsomes and observed that the relative amount of -OHALP formed in
brain was higher than liver. This biotransformation was mediated by a P450
isoform belonging to P4503A subfamily, which is constitutively expressed in
neuronal cells in rat and human brain. The formation of larger amounts of
-OHALP in neurons points to local modulation of pharmacological activity
in brain, at the site of action of the anti-anxiety drug. Since hydroxy metab-
olites of alprazolam are hydrophilic and not easily cleared through blood-
CSF barrier, -OHALP would potentially have a longer half-life in brain.
The Pharmacogenomics Journal (2002) 2, 243–258. doi:10.1038/
sj.tpj.6500115
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INTRODUCTION
Cytochromes P450 (E.C. 1.14.14.1; P450) and associated mono-oxygenases are
one of the most important class of drug metabolizing enzymes in the body.1 This
family of heme proteins exists in multiple forms having distinct yet overlapping,
substrate specificities and are encoded by a supergene family, several members
of which have been well characterized.2 The multiple forms of P450 are distinct
gene products and have been classified into 36 gene families. The individual
P450s are represented by an Arabic number denoting the family, followed by an
alphabetical letter designating the sub-family and an Arabic numeral rep-
resenting the individual gene within the subfamily.2 Thus, the individual hepatic
isoforms P4503A4 present in human and P4503A1 in rat both belong to the
P4503A sub-family. P450 dependent mono-oxygenases are found predominantly
in the microsomal fraction of tissues, but such activities are also present in mito-
chondrial fraction. The microsomal P450 mono-oxygenase enzyme system
(which is of present interest) has three major components: (a) the heme protein,
cytochrome P450 (P450); (b) the flavoprotein, NADPH cytochrome P450
reductase (reductase); and (c) phospholipid. Reductase helps the transfer of elec-
trons from NADPH to the heme protein and is an essential component of the
P450 monooxygenase system.
P450 mediated metabolism can lead to the detoxification of drugs rendering
them pharmacologically inactive, or on the other hand, bioactivation can also
take place wherein a drug can be metabolized to pharmacologically active metab-
olite3 which may have longer or shorter half life compared to parent drug. Metab-
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olism may be necessary for pharmacological action, if
metabolite is active, and if metabolite is inactive, this would
result in cessation of drug action.
Psychoactive drugs, such as antidepressants and neuro-
leptics are metabolized by hepatic P450. Specific forms of
hepatic P450s such as those belonging to 3A, 2D, 2C and
1A subfamilies are involved in the metabolism of some of
these drugs in both rat and human liver.4,5 The major differ-
ences that are seen between the rat and human hepatic
P450s is the distribution of the multiple forms. For example,
amongst the isoforms of P450 belonging to the P4503A
subfamily, P4503A4 is the predominant form of P450 in
human liver and can account for nearly 60% of the total
P450 present. In the rat liver, the analogous P4503A1 rep-
resents a relatively minor form of P450.6
It has long been appreciated that the liver is quantitatively
the major organ involved in metabolic disposition of most
xenobiotics, in vivo.7 However, the importance of extrahep-
atic metabolism has been increasingly recognized especially
during the past 2 decades. This has prompted extensive
investigations into the xenobiotic metabolizing capability of
extrahepatic organs in laboratory animals such as rat. Kid-
ney, lung and nasal epithelium that are anatomically dis-
posed to high levels of exposure to potential toxicants have
been studied in rats.8 The preferential localization of drug
metabolizing enzymes within specific cell types in these
organs renders such cells significant capability to metabolize
drugs.9 Thus, even minor metabolic pathways of xenobiotic
metabolism can produce significant effects if it takes place
at the site of action. These observations have prompted
investigation into P450 associated mono-oxygenases in
brain, with an effort to determine the capability of the brain
to metabolize psychoactive drugs.10
P450 mediated metabolism of psychoactive drugs directly
in the brain may lead to local pharmacological modulation
at the site of action and result in variable drug response.
Plasma drug levels which are often used as indicators of bio-
availability of a drug reflect the variability in hepatic drug
metabolism. However, it is being increasingly recognized
that: (i) significant number of patients with adequate plasma
levels do not respond to psychoactive drugs; and (ii) patients
with acceptable plasma levels of drugs exhibit toxic side
effects due to the drug. Thus, plasma levels of drugs are not
always effective indicators of therapeutic outcome.11
Recent studies from our laboratory and others have dem-
onstrated the presence of a competent microsomal P450 sys-
tem in the rodent12 and human13 brain and its ability to
metabolize a variety of xenobiotics. The appearance of mul-
tiple forms of P450 in brain and their selective inducibility
by phenobarbital, 3-methylcholanthrene, -naphthoflavone
and ethanol have also been identified.10 However, we know
little about the ability of the brain P450 to metabolize psy-
choactive drugs and the potential consequence of such
biotransformation at the site of action of these drugs.
Alprazolam is an extensively used anti-anxiety drug. In rat
and human liver, it is biotransformed to hydroxylated
metabolites, 4-hydroxy alprazolam (4-OHALP) and -hyd-
roxy alprazolam (-OHALP). While, -OHALP, the minor
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metabolite is pharmacologically more active, 4-OHALP, the
major metabolite is less active.14 This offered us an unique
opportunity to test whether pharmacologically active
metabolite(s) were formed in brain and more importantly if
the metabolic profile differed between brain and liver, since
hepatic biotransformation pathways cannot be often
extrapolated to the brain. We, therefore examined the
metabolism of alprazolam by rat liver and brain microsomes
and compared it with the activity in microsomes prepared
from human brain regions obtained at autopsy.
RESULTS
Metabolism of Alprazolam by Rat Brain Microsomes
Rat brain microsomes metabolized alprazolam to 4-hydroxy
and -hydroxy alprazolam. The activities were 5.44  0.134
pmoles of 4-hydroxy alprazolam formed min1 mg1 pro-
tein and 2.42  0.16 pmoles of -hydroxy alprazolam for-
med min1 mg1 protein (n = 5 sets of microsomes prepared
from pooled brains of ten rats). There was no detectable
hydroxylation of alprazolam in incubations that did not
contain NADPH or substrate. The 4-hydroxylase activity in
control rat brain microsomes increased linearly over a pro-
tein concentration of 0.5–2 mg per ml incubation and over
a time period of 5–30 min, but declined subsequently due
to the instability of the metabolite. The metabolism of alpra-
zolam to -hydroxy alprazolam was linear over a protein
concentration of 0.5–2 mg of microsomal protein ml1 incu-
bation however, the amount of metabolite formed decreased
by over 50% when the incubation time was increased from
15–30 min due to the known instability of the metabolite.
The amount of metabolite formed was constant from 5–15
min (data not shown). All incubations were therefore perfor-
med for 15 min and the metabolite(s) were assayed by HPLC
within 30 min after completion of incubation. The Km and
Vmax for the formation of 4-hydroxy and -hydroxy alpra-
zolam are given in Table 1. The rate of formation of 4-hyd-
roxy alprazolam was about three-fold higher than that for
-hydroxy metabolite.
Distribution of Alprazolam Hydroxylase Activity in
Human Brain Regions
We examined hydroxylation of alprazolam by different
regions of human brain (cortex, cerebellum, straitum and
Table 1 Apparent Km and Vmax for the hydroxylation of
alprazolam to its hydroxylated metabolites by rat and
human brain microsomes
-OH ALP 4-OH ALP
Km Vmax Km Vmax
Rat 0.211 2.03 0.56 7.48
Subject I 8.868 3.37 0.83 9.07
Subject II 3.56 12.77 3.2 21.96
Subject III 5.79 16.52 3.39 26.29
Apparent Km and Vmax calculated from Eadie–Hofstee plot are expressed as mM
and picomoles of -hydroxy alprazolam (-OHALP) and 4-hydroxy alprazolam (4-
OHALP) formed min1mg1 protein, respectively.
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thalamus) as depicted in Figure 1. Maximal activity was seen
in the striatum for both the metabolites. All the brain
regions examined were capable of metabolizing alprazolam
to both the hydroxylated metabolites. The activity varied
from 2.4–4.9 pmoles of 4-hydroxy alprazolam formed min1
mg1 protein and 0.7–0.96 pmoles of -hydroxy alprazolam
formed min1 mg1 protein. No significant differences were
seen amongst the brain regions examined. The human brain
microsomal P450 mediated formation of 4-hydroxy alprazo-
lam was linear through a protein concentration of 0.5–2 mg
protein ml1 and over a time period of 5–30 min. The forma-
tion of -hydroxy alprazolam increased linearly when the
protein concentration was increased from 0.5–2 mg. How-
ever, the activity was linear only over a short time period of
5–15 min and thereafter remained nearly constant up to 30
min. The Km and Vmax for the formation of both the
hydroxylated metabolites by human brain cortical micro-
somes is given in Table 1. Significant inter–individual differ-
ences were noted in the apparent affinity and velocity con-
stants for the formation of the hydroxylated metabolites
amongst the different human brains examined. A common
feature was the relatively low affinity (Km = 0.8–8.8 mM)
for the alprazolam. However, this needs to be interpreted
with caution, since the brain microsomes used for the assay
of mono-oxygenase activity have contributions from both
the glial and neuronal cells (unlike in liver) although the
Figure 1 Metabolism of ALP to 4-OHALP and -OHALP by human
brain microsomes. Microsomes (1 mg protein ml1) prepared from
brain regions of human autopsy tissue were incubated with 1mM
ALP for 15 min in presence of NADPH. The amount of 4-OHALP and
-OHALP formed were estimated. Values are average of duplicate
analysis of brain regions obtained from four individuals. Data is
presented as mean  SD (n = 4 subjects). The brain regions are
represented as CT-cortex, CE-cerebellum, ST-striatum, TH-thala-
mus.
www.nature.com/tpj
P450 is selectively localized in specific cell population. Stud-
ies with the purified enzyme would yield more accurate
information on the kinetics of the enzyme.
Inhibition of Alprazolam Hydroxylase Activity in Rat
and Human Brain Microsomes
We incubated microsomes from rat (Figure 2a) and human
brain cortex (Figure 2b) with the common inhibitor of P450,
piperonyl butoxide prior to estimation of enzyme activity.
This pretreatment resulted in the inhibition of alprazolam
hydroxylase activities by 60% of 4-hydroxy alprazolam and
85% of -hydroxy alprazolam in rat brain as compared to
control and by 77% of 4-hydroxy alprazolam and 70% of
-hydroxy alprazolam as compared to controls in human
brain, indicating that the metabolism was indeed mediated
by P450. Preincubation with quinidine, an inhibitor of
P4502D had a substantially lower inhibitory effect on the
hydroxylase activities as compared to ketoconazole (a spe-
cific inhibitor of P4503A). Further, preincubation of the rat
brain microsomes with the antiserum to P4503A resulted in
the inhibition of alprazolam hydroxylase activities by 89%
of 4-hydroxy alprazolam and 86% of -hydroxy alprazolam
as compared to non-immune serum, indicating that the
biotransformation were indeed mediated by P4503A.
Relative Rates of Formation of 4-Hydroxy and
-Hydroxy Alprazolam by Rat and Human Brain
Microsomes
We measured the rate of formation of 4-hydroxy and -hyd-
roxy alprazolam by rat liver and brain microsomes. In rat
liver, the rates of formation of 4-hydroxy and -hydroxy
alprazolam were 167.7 and 3.2 pmol min1 mg1 protein,
respectively. Thus, the rate of formation of -hydroxy alpra-
zolam is about 1.9% of the total 4-hydroxy alprazolam for-
med after 15 min of microsomal incubation in presence of
NADPH. In brain, the rates of formation of 4-hydroxy and
-hydroxy alprazolam were 5.44 and 2.42 pmol min1 mg1
protein, respectively, thus indicating that the amount of -
hydroxy alprazolam formed was 44.5% of the total 4-hyd-
roxy alprazolam after similar incubation period of 15 min
(Figure 3a). When we looked at the relative rates of forma-
tion of the hydroxylated metabolites after shorter incu-
bation periods, such as 5–10 min, we found that the amount
of -hydroxy alprazolam formed in brain microsomes after
5 min of incubation was 35% more than the detectable
amount of 4-hydroxy alprazolam indicating that -hydroxy
alprazolam which is known to be relatively unstable, was
undergoing degradation during longer incubation periods.
Thus, -hydroxy alprazolam (which is pharmacologically
more active) formed in greater amounts in the brain as com-
pared to liver, but since this metabolite has a tendency to
degrade during microsomal incubation relatively lesser
amounts are detected during longer microsomal incu-
bations. -Hydroxy alprazolam was also formed in relatively
larger amounts in human brain microsomal incubations
(Figure 3b).
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Northern Blot Analysis of CYP3A Expression in Rat
Brain
Northern blot analysis of total RNA from rat and human
brain cortex demonstrated the expression of transcripts
belonging to CYP3A subfamily. The molecular mass of the
transcript was approximately 1.6 Kb (Figure 4).
The Pharmacogenomics Journal
Figure 2 Effect of inhibitors and antiserum to P4503A4 on the for-
mation of 4-OHALP and -OHALP by rat (a) and human (b) brain
microsomes. Microsomal incubations were carried out in presence
of PIP (piperonyl butoxide 0.5 mM), QUIN (quinidine 1mM), KET
(ketoconazole 5 M), or CON (in absence of any of the above) and
NIS (nonimmune serum 50 l) or IS (immune serum 50 l). Data
represents the amount of metabolites formed min1 mg1 protein
as percent of the control values (CON). Values are (a) mean  SD
from three different batches of rat brain microsomes and (b) mean
 SD (n = 4 subjects).
Figure 3 Relative rates of formation of -OHALP and 4-OHALP
from ALP by rat (a) brain and liver and human brain (b) micro-
somes. Relative amounts of the hydroxylated metabolites formed
are expressed as percent of 4-OHALP formed at varying time per-
iods. Empty bars represent 4-OHALP and filled bars represents
-OHALP. The values are average of three analysis. The rates of
formation of 4-hydroxy alprazolam and -hydroxy alprazolam in
liver after 15 min of microsomal incubation were 167.7 and 3.23
pmoles of product formed min1 mg1 protein, respectively. In rat
brain, under similar conditions, the rates were 5.44 and 2.4 pmoles
of hydroxylated metabolites formed, while in the human brain the
rates were 2.03 and 1.15 pmoles of product formed min1 mg1
protein.
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Figure 4 Northern blot analysis showing the constitutive
expression of CYP3A mRNA in rat and human brain. Total RNA from
rat brain cortex (lane 1, 12 g) and human brain cortex (lane 2, 6
g) were electrophoresed under denaturing conditions. After
transfer to nylon membrane, the blots were hybridized with anti-
sense riboprobe prepared using cDNA to CYP3A1. The mobility of
the 18S and 28S ribosomal RNA is indicated. The CYP3A mRNA in
rat and human brain was seen as a band at approximately 1.6 Kb.
Localization of CYP3A mRNA in Rat Brain by
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) studies demon-
strated the presence of mRNA belonging to CYP3A subfam-
ily predominantly in neuronal cells in rat brain regions. The
neuronal cells in the cerebral cortex showed intense cyto-
solic staining, indicating the presence of the CYP3A mRNA
(Figure 5a), while the sections hybridized with the sense
probe showed no fluorescence (Figure 5b). In the cerebel-
lum, the Purkinje cells showed intense fluorescence, while
the granule cell layer was relatively less intensely stained
(Figure 5c). Intense fluorescence was seen in hippocampus,
in the pyramidal neurons of CA1, CA2 and CA3, and in the
granule cell layer in the dentate gyrus (Figure 5e), while
similar sections hybridized with the sense digoxigenin lab-
eled probe showed no fluorescence (Figure 5f). Neurons in
the thalamus were also stained indicating the presence of
CYP3A (Figure 6a). In the mid-brain, the reticular neurons
were selectively labeled, indicating the predominant pres-
ence of CYP3A mRNA in these cell populations (Figure 6b).
In the cervical region of the spinal cord, the neurons were
intensely stained including the large anterior horn cell
(Figure 6c and d).
Localization of CYP3A mRNA in Human Brain by
Fluorescence in situ Hybridization
Fluorescence in situ hybridization (FISH) studies demon-
strated the presence of CYP3A mRNA predominantly in neu-
ronal cells in human brain regions. High levels of CYP3A
www.nature.com/tpj
mRNA was seen in neuronal cells in the cerebral cortex
(Figure 7a), while sections hybridized with the sense probe
showed no fluorescence (Figure 7b). In the cerebellum, Purk-
inje cells showed intense fluorescence while the granule cell
layer was less stained (Figure 7c). The reticular neurons in
mid-brain were also labeled indicating the presence of
CYP3A mRNA (Figure 7e). Intense fluorescence was seen in
hippocampus (Figure 8), in the pyramidal neurons of CA1,
CA2 and CA3 subfields and in the granule cell layer in the
dentate gyrus, while similar sections hybridized with the
sense digoxigenin labeled probe showed no fluorescence
(Figure 8d). The pyramidal neurons in CA1 showed intense
cytosolic staining (Figure 8c). The neurons in CA2 were also
labeled and the compact CA2 neuronal cell layer was clearly
discernable (Figure 8a). In CA3, pyramidal neurons were
intensely fluorescent (Figure 8b), along with the interneu-
rons of the hilius. The granule cell layer of the dentate gyrus
was also intensely stained (Figure 8b) indicating the pres-
ence of high amounts of CYP3A mRNA, similar to that seen
in the rat brain.
Immunoblot Analysis of Microsomes from Rat and
Human Brain Using Antiserum to Hepatic P4503A
Immunoblot analysis of rat brain microsomal proteins using
antiserum to the hepatic P4503A4 showed the constitutive
presence of P4503A in the brain regions of untreated rat
brain (Figure 9a). Similar immunoblot studies were carried
out using microsomes prepared from human brain regions
obtained at autopsy (Figure 9b). The constitutive presence
of P4503A was detectable in all the brain regions examined
in both rat and human brain. An immunoreactive protein
of molecular weight approximately 52.8 kDa was detectable
in microsomes prepared from various regions of human
brains such as cortex, cerebellum, striatum and hippocam-
pus (Figure 9).
Immunohistochemical Localization of P4503A in Rat
Brain
Immunohistochemical studies demonstrated the presence of
P4503A protein predominantly in neuronal cells in rat
brain. Intense immunostaining was observed in neurons in
rat brain cortex indicating the presence of P4503A (Figure
10d). At higher magnification (Figure 10e) immunostaining
of apical dendrites was also observed. No immunostaining
was seen in control sections pretreated with non-immune
serum (Figure 10f). Intense immunostaining of neurons in
olfactory bulb was seen, indicating presence of P4503A
(Figure 10a). The neurons in the olfactory glomeruli were
intensely stained (Figure 10b). No staining was seen in exter-
nal plexiform layer (EPL) while the granule cell layer (GL)
was intensely stained (Figure 10a). Significant immunostain-
ing of cerebellar granular cell layer (GL) and sparse staining
of the cells in the molecular layer (ML) was observed (Figure
11a1). Immunostaining was seen in CA1, CA2 and CA3
subfields of hippocampus (Figure 11d1) and granular cell
layer of the dentate gyrus (arrow in Figure 11e1) was
intensely stained. The interneurons of the hilius and CA3
pyramidal neurons were also immunostained (Figure 11e1).
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Figure 5 Localization of CYP3A mRNA in rat brain using fluorescence in situ hybridization. (a) The presence of CYP3A in the neurons
of cerebral cortex (arrow); Bar = 50 m. (b) Control section hybridized with the sense probe; Bar = 100 m. (c) Fluorescent labelling of
the Purkinje cells (arrow), in the rat cerebellum; Bar = 50 m. Control section of rat cerebellum hybridized with sense probe is depicted
in (d); Bar = 100 m. (e) Intense fluorescence was seen in granule cell layer of the dentate gyrus (arrow). The CA1, CA2 and CA3 subfields
of the hippocampus was also intensely fluorescent; Bar = 200 m. (f) Control sections hybridized with sense probe showed no fluor-
escence; Bar = 100 m.
Immunostaining of striatal neurons was observed indicat-
ing the presence of P4503A protein (Figure 12a2 and b2).
Expression of P4503A was also seen in midbrain region of
rat brain (Figure 12f2). P4503A expression was also seen in
the neurons of the anteroventral nucleus of thalamus
(Figure 12e2). Intense staining was seen in the island of Cal-
leja (arrow in Figure 12c2) indicating the presence of
P4503A in these regions. Staining of glial cells in the corpus
callosum was also observed (Figure 12d2).
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Localization of P4503A by Immunofluorescence
Immunofluorescence analysis using antiserum to liver
P4503A demonstrated the predominant presence of P4503A
in neuronal population in concordance with the in situ
experiments. In the cerebellum, granule cells and Purkinje
cells were stained (Figure 13a), with the Purkinje cells being
more intensely stained compared to granule cells, similar to
the observation made in the in situ studies. Fluorescent
staining of the neuronal cell body and apical dendrites was
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Figure 6 Localization of CYP3A mRNA in control rat brain using fluorescence in situ hybridization. (a) CYP3A mRNA was observed in
the ventral nucleus of the thalamus and in the fimbria of the hippocampus (arrow); Bar = 200 m. Inset: higher magnification of a giant
reticular neuron. (b) The intense fluorescence of reticular neurons in the midbrain expressed the CYP3A mRNA; Bar = 200 m. (c) Intense
fluorescence was seen in the spinal cord section; Bar = 200 m. (d) The anterior horn cells of the spinal cord (arrow) were intensely
fluorescent indicating the substantial expression of CYP3A; Bar = 50 m.
seen in frontal cortex (Figure 13d). The CA1 neurons in the
hippocampus were also stained (Figure 14a and b) where
immunostaining was also observed in the synaptic ter-
minals. Reticular neurons of the midbrain (Figure 14d and
e) were also immunostained. Similar sections incubated with
non-immune serum did not show any staining (Figure 14f).
DISCUSSION
Hydroxylation of drugs by hepatic P450 results in the forma-
tion of hydrophilic metabolites, which can be easily
excreted by the kidney. However, if such hydroxylated
metabolites were to be formed in the brain it would result
in their prolonged presence due to the presence of the
blood-CSF barrier. The two hydroxylated metabolites of alp-
razolam are known to have differential pharmacological
effects. -Hydroxy alprazolam has about 77% of the intrinsic
pharmacological activity of the parent drug, while 4-hyd-
roxy alprazolam has only about 14% of the activity.14 How-
ever, since the plasma levels of both the hydroxylated
metabolites are considerably lower than the parent drug in
humans,15 it has been concluded that they do not play any
significant role in the anti-anxiety effects of alprazolam,
which are mediated in the brain. This study presents the first
evidence for the formation of the hydroxylated metabolites
www.nature.com/tpj
of alprazolam in situ, at the site of action, in the brain where
they can exert pharmacological action regardless of the
plasma concentration. This is of significance since the
hydroxylated metabolites would potentially have a pro-
longed presence and lowered clearance from brain.10
Further, since the isoform of P450 belonging to the P4503A
sub-family which mediates alprazolam metabolism in the
brain is localized predominantly in neuronal cell population
(Figure 5), the site of action of these drugs, the intrinsic con-
centration of these metabolites in the neuronal cells may be
significant enough to play a role in the local pharmacologi-
cal action of the drug. Further, the activity measurements
reported in the present study have been ascertained using
microsomes prepared from the brain tissue, which com-
prises of both glial and neuronal cells. The measured activity
would be the average of the contributions by the neuronal
and glial cells, thus under-estimating the biotransformation
in the neurons. P4503A is localized in the neurons in the
cortex, cerebellum, olfactory tubercle and hippocampus of
rat brain which co-localizes with the benzodiazepine bind-
ing sites in GABAA receptor, such as, neuronal cell layers in
cerebral cortex, granule cell layers of cerebellum, dentate
gyrus and pyramidal cell layers (CA1, CA2 and CA3) of hip-
pocampus, olfactory tubercle, island of Calleja and thala-
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Figure 7 Localization of CYP3A mRNA in human brain by fluorescent in situ hybridization. (a) Intense fluorescence was seen in the
neuronal cell layers of the human brain cortex; Scale bar = 200 m. Inset: higher magnification of a fluorescent cortical neuron expressing
CYP3A mRNA. (b) Control section hybridized with sense probe did not show any fluorescence; Scale bar = 100 m. (c) Fluorescent
labeling of the Purkinje cells (arrow) and the granule cell layer (GL) was seen in the human cerebellum. Sparse staining of the cells in
the molecular layer (ML) was also noted; Scale bar = 50 m. Inset: higher magnification of the Purkinje neurons. Control section of the
human cerebellum hybridized with the sense probe is depicted in (d); Scale bar = 100 m. (e) The reticular neurons in the midbrain
expressed CYP3A mRNA; Scale bar = 50 m. Inset: higher magnification of a reticular neuron. (f) Control section of midbrain hybridized
with the sense probe; Scale bar = 100 m.
mus16 indicating that the metabolism of alprazolam to its
pharmacologically active metabolite could occur at the site
of drug action.
Another important finding in the present study, being
reported for the first time, is the intrinsic difference in the
metabolite profile seen in brain and liver. While it has been
The Pharmacogenomics Journal
observed that the P450 levels in the brain are one-tenth to
one-fifteenth of that typically seen in liver and it is generally
acknowledged that the capability of the brain to effect P450
mediated metabolism of drugs is also substantially lower,
the observations made in this study demonstrate that the
above considerations not withstanding, pharmacologically
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Figure 8 Localization of CYP3A mRNA in human brain by fluorescent in situ hybridization. (a) The presence of CYP3A mRNA in the
pyramidal neurons of CA2 subfield in the hippocampus (arrow) is depicted; Scale bar = 200 m. (b) A view of fluorescent granule cell
layer of the dentate gyrus (double arrow) is presented, intense fluorescence of the hilial neurons (arrow) and CA3 pyramidal neurons
is also seen; Scale bar = 200 m. (c) The presence of CYP3A mRNA was observed in CA1 neurons (arrow) which were intensely fluorescent;
Scale bar = 200 m. Inset: higher magnification of CA1 neuron. (d) Control section hybridized with sense probe did not exhibit any
fluorescence; Scale bar = 100 m.
active metabolites can be formed in significant amounts in
the brain. Thus, in rat and human brain, -hydroxy alprazo-
lam is formed in relatively higher amounts than in the liver.
While, the amount of 4-hydroxy alprazolam formed in rat
brain is 3.2% of the concentration in liver, -hydroxy alpra-
zolam concentration is 75% of the corresponding level in
liver. Further, in the liver 4-hydroxy alprazolam is the major
metabolite and concentration of the -hydroxy metabolite
is only 1.9% of the corresponding 4-hydroxy alprazolam lev-
els. However, in the brain, after 15 min microsomal incu-
bation, we find that the relative concentration of -hydroxy
metabolite is 44.5% of the 4-hydroxy metabolite. -Hydroxy
alprazolam is known to be unstable under experimental
conditions, therefore we measured the relative amounts of
metabolites formed after shorter incubation periods (Figure
3). -Hydroxy alprazolam is formed in greater amounts than
4-hydroxy alprazolam in rat brain microsomal incubation,
while this is not reflected in experiments using rat liver
microsomes.
The studies carried out using rat brain microsomes were
replicated using human autopsy brain tissue obtained from
traffic accident victims. Our earlier studies have shown that
the brain P450 levels and NADPH cytochrome c reductase
activity (an essential component of P450 mono-oxygenase
www.nature.com/tpj
system) are preserved in brain up to 12 h of post-mortem
delay.17 The tissues used in these studies were obtained
within this time period.
Thus, the present study demonstrates the capability of the
human brain to metabolize alprazolam to its hydroxylated
metabolites, but more importantly, in a manner similar to
that seen in rat brain, -hydroxy alprazolam, the pharmaco-
logically more active metabolite, was formed in relatively
greater amounts as compared to 4-hydroxy alprazolam. Our
results are in agreement with the studies of Banks et al18
where a single dose of 14C-alprazolam was administered to
rats and the levels of the parent drug and the hydroxylated
metabolites were measured in plasma and brain. They
observed that the plasma concentration of -hydroxy alpra-
zolam (13% of 4-hydroxy alprazolam concentration) was
quite low, while in the brain although the absolute concen-
tration of the hydroxylated metabolites was low, -hydroxy
alprazolam concentration was 266% of 4-hydroxy alprazol-
am.
The salient features of the current study are that it
presents conclusive evidence for differences in the metab-
olism of drugs in liver, the major organ involved in
biotransformation of drugs and the brain, the site of action
of a variety of psychoactive drugs which are used extensively
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Figure 9 Immunoblot analysis of microsomal protein from rat (A)
and human (B) brain regions stained with antiserum to hepatic
P4503A. Microsomal protein (50 g) prepared from rat (a) and
human (b) brain regions were subjected to SDS–PAGE followed by
immunoblotting onto nitrocellulose membrane with antiserum to
P4503A4. Immunostained bands were detected at 52.8 KDa. (a) The
lanes contained microsomal protein from rat brain cerebral cortex
(lane 1), cerebellum (lane 2), midbrain (lane 3), hippocampus (lane
4) and thalamus (lane 5). (b) Immunostained bands were also
detectable in microsomes from human brain regions such as cortex
(lane 2), cerebellum (lane 3), striatum (lane 4) and hippocampus
(lane 5) from subject II. Lane 1 was loaded with molecular weight
markers indicated by arrows (top to bottom—198, 113, 75, 48.9,
17.4 and 6.8 KDa, respectively).
in the treatment of mental illnesses and often for prolonged
periods of time. The striking differences seen in the metab-
olism of alprazolam in liver and brain, and more
importantly the formation of greater amounts of -hydroxy
alprazolam, the pharmacologically more active metabolite,
points to the need for examining the metabolism of drugs
at their site of action rather than taking hepatic metabolism
alone into account. This is also important because brain
P450 forms are different from liver; for example P4503A1 is
induced by phenobarbital in rat liver but not in brain.19
These are relevant not only for known drugs, but also newer
drugs which are in the discovery and development stage.
The similarities seen in the metabolic capability between rat
and human brain indicate that experiments using rat brain
microsomes can be used as a pointer to understand potential
metabolism in human brain tissue.
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In conclusion, the present study demonstrates the sig-
nificant differences that exist between hepatic and cerebral
metabolism of drugs such as alprazolam and suggest the
importance of understanding biotransformation pathways
in brain. Of particular importance are the observations made
using human brain tissue, which not only provide the first
evidence for metabolism of psychoactive drugs in human
brain, but also demonstrate the constitutive expression of
the enzyme involved in the biotransformation and its local-
ization in the neuronal cells, the site of action of these
drugs.
MATERIALS AND METHODS
Materials
Alprazolam and its two principal metabolites, 4-OHALP and
-OHALP were obtained as gifts from Upjohn Company,
Kalamazoo, MI, USA. Dithiothreitol, phenylmethyl sulfonyl
fluoride, aprotinin, leupeptin and NADPH were purchased
from Sigma Chemical, USA. Northern blot analysis was per-
formed using the digoxigenin labeling kit from Boehringer
Mannheim, Germany. Fluorescent in situ hybridization
experiments were performed using the tyramide signal–
amplification kit from NEN Life Sciences Products, USA.
Animals
Male Wistar rats (3–4 months, 225–250 g) were obtained
from the Central Animal Research Facility of the National
Institute of Mental Health and Neurosciences. Animals had
access to a pelleted diet (Lipton India, Calcutta, India) and
water ad libitium. All animal experiments were carried out
in accordance with the National Institutes of Health guide-
lines for the care and use of laboratory animals and were
approved by the institutional ethics committee. All efforts
were made to minimize animal suffering, to reduce number
of animals used, and to utilize alternatives to in vivo tech-
niques, if available.
Human Brain Tissue
Human brain, from traffic accident victims was obtained
from the Human Brain Tissue Repository of the Institute.
Both male and female brains were used. The age and gender
of the subjects are: (subject I) 51 year old female
(postmortem delay 10 h); (subject II) 32 year old male
(postmortem delay 4 h); (subject III) 8 year old female
(postmortem delay 8 h); (subject IV) 65 year old male
(postmortem delay 6 h); and (subject V) 21 year old male
(postmortem delay 1.5 h). After autopsy, the brains were
washed in ice-cold saline and dissected into different regions
such as cortex, cerebellum, hippocampus, striatum, mid-
brain and thalamus based on standard anatomical markings.
All regions were frozen and stored at 70°C immediately.
These tissues were thawed on ice prior to the preparation of
microsomes as described below.
Preparation of Microsomes
Animals were anesthetized with ether and perfused transcar-
dially with ice-cold Tris buffer (100 mM, pH 7.4) containing
KCl (1.15% w/v) prior to decapitation and removal of brain.
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Figure 10 Localization of P4503A in rat brain by immunohistochemical analyses. (a) Intense immunolabelling of neurons in olfactory
bulb was seen, indicating presence of P4503A. The neurons in the glomeruli (arrow) were intensely stained. No staining was seen in
external plexiform layer (EPL) while the granule cell layer (GL) was intensely stained; Bar = 100 m. (b). Higher magnification of the
glomeruli in the olfactory bulb; Bar = 25 m. (c) Control section incubated with non-immune serum did not show immunostaining in
the olfactory bulb; Bar = 100 m. (d) Rat brain section showing intense immunostaining of cortical neurons indicating the presence of
P4503A; Bar = 100 m. (e) Higher magnification of cortical neurons showing intense immunostaining; Bar = 10 m. (f) Control section
pretreated with non-immune serum did not show immunostaining in the cerebral cortex; Bar = 100 m.
Whole brain from rats (tissue pooled from 8–10 rats) or
human brain regions or rat brain regions (cortex, cerebel-
lum, mid-brain, hippocampus and thalamus) were dissected
out using standard anatomical landmarks.20 The tissues were
www.nature.com/tpj
homogenized using a Potter–Elvehjem homogenizer in nine
volumes of ice-cold Tris buffer (0.1 mM), EDTA (0.1 mM),
KCl (1.15% w/v), phenyl methyl sulfonyl fluoride (0.1 mM),
butylated hydroxytoluene (22 M), glycerol (20%, v/v),
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Figure 11 Localization of P4503A in rat brain by immuno-histochemical analyses. (a1) Intense immunostaining of granular cell layer (GL)
of cerebellum was seen, while the molecular layer (ML) was sparsely stained; Bar = 200 m. (b1) Higher magnification of cerebellum
showing intense staining of the granule cell layer (arrow head) and Purkinje cells (arrow) indicating the presence of P4503A; Bar = 25
m. (c1) No staining was seen in cerebellum section treated with non-immune serum; Bar = 200 m. (d1) Intense immunostaining of
P4503A in dentate gyrus (DG), CA1, CA2 and CA3 subfields of hippocampus; Bar = 200 m. (e1) Higher magnification of the granular
cell layer of the dentate gyrus (arrow) showing intense immunostaining for P4503A. Staining of the interneurons of the hilius (arrowhead)
was also observed; Bar = 50 m. (f1) Higher magnification of the CA1 pyramidal neurons showing the presence of P4503A; Bar = 25 m.
aprotinin (0.001%, w/v) and leupeptin (0.001%, w/v), pre-
viously bubbled with nitrogen (buffer A). The homogenate
was centrifuged at 17 000 g for 30 min at 4°C. Thereafter,
the supernatant was centrifuged at 100 000 g for 1 h to give
the microsomal pellet. The pellet was suspended in a small
volume of buffer A, aliquoted, flash–frozen in liquid nitro-
gen and stored at 70°C. The protein concentration was
measured by dye-binding method.21
HPLC Assay of Alprazolam
Brain microsomal incubation (2 ml) was performed in Tris–
HCl buffer (50mM, pH 7.4) containing MgCl2 (20 mM),
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microsomal protein (0.5 mg–2 mg ml2 of incubation) and
alprazolam (0.25–1.5 mM). The reaction was initiated by
addition of NADPH (1 mM final concentration) after prein-
cubation at 37°C for 4 min. Blanks containing no NADPH
or substrate were also run simultaneously. The reaction was
terminated after 15–60 min by the addition of NH4OH
(0.1%, v/v) and 5 ml of dichloromethane. The microsomal
incubations were vortexed, centrifuged at 4000 g (5 min)
and the lower organic phase was pooled and evaporated
under nitrogen atmosphere at 45°C . The residue was dis-
solved in 0.4 ml of the HPLC mobile phase consisting of
potassium phosphate buffer (50 mM, pH 9) containing ace-
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Figure 12 Localization of P4503A in rat brain by immunohistochemical analyses. (a2) Immunostaining of striatal neurons indicating the
presence of P4503A; Bar = 200 m. (b2) Higher magnification of the striatal neurons showing the presence of P4503A; Bar = 25 m.
(c2) Intense staining was seen in island of Calleja (arrow) and in the diagonal band of Broca (DBB) indicating the presence of P4503A;
Bar = 25 m. (d2) Staining of cells was also seen in corpus callosum; Bar = 25 m. (e2) The neurons in the anteroventral nucleus of the
thalamus were immunostained (arrows); Bar = 25 m. (f2) Immunostaining of reticular neuron (arrow) in the midbrain indicating the
presence of P4503A; Bar = 25 m.
tonitrile (30% v/v), filtered and injected onto an HPLC col-
umn consisting of SUPELCOSIL (LC-18 column) at a flow
rate of 1 ml min1. The formation of metabolites (4-OHALP
and -OHALP) was detected by monitoring the UV absorp-
tion at 224 nm. The amount of metabolites formed was esti-
mated from the standard curve. All analysis was performed
in duplicates.
Inhibition Experiments
Immunoinhibition was performed by preincubation of rat
brain and human cortical microsomes with varying concen-
trations of non-immune serum or antiserum to rat liver
P4503A4 for 30 min at 37°C prior to the assay of alprazolam
metabolism. Chemical inhibition was performed by prein-
cubation of microsomes with piperonyl butoxide (0.5 mM
www.nature.com/tpj
final concentration), quinidine (1 mM final concentration)
or ketoconazole (5 M final concentration) for 30 min. at
37°C prior to the addition of substrate and NADPH for
microsomal incubation.
Immunoblot Analyses
Microsomal proteins from rat (50 g) and human (50 g)
brain regions were subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis.22 Proteins were trans-
ferred from the gel to nitrocellulose membranes.23 The
membranes were immunostained with antiserum to liver
P4503A4, followed by incubation with anti rabbit IgG lab-
eled with alkaline phosphatase (Vector Laboratories, USA.).
The immunostained bands were detected using nitroblue
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Figure 13 Localization of P4503A in human brain cortex and cerebellum by immunofluorescence analyses. (a) Localization of P4503A
in the Purkinje cell is depicted; Bar = 100 m. (b) Higher magnification of the Purkinje neurons; Bar = 25 m. (c) Control section incubated
with non-immune serum did not show immunostaining in the cerebellum; Bar = 100 m. (d) Immunolabelling of neurons in frontal
cortex was seen indicating the presence of P4503A; Bar = 100 m. (e) Higher magnification of the immunostained cortical neurons
depicting the fluorescence in the apical dendrites; Bar = 25 m. (f) No staining was seen in cerebral cortex section incubated with non-
immune serum; Bar = 100 m.
tetrazolium and 5-bromo 4-chloro 3-indolyl phosphate as
chromogens.
Northern Blotting and Fluorescence in-situ
Hybridization
cDNA to rat liver CYP3A1 was obtained as a gift from Dr
Avadhani, USA, was used for the preparation of riboprobes.
The total RNA was extracted from rat brain (cortex) and liver
and human brain cortex as described by Chomezynski.24
Total RNA was separated electrophoretically and transferred
onto positively charged nylon membrane by capillary trans-
fer,25 UV cross linked and hybridized with digoxigenin lab-
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eled antisense riboprobe prepared using SP6 polymerase to
CYP3A1. The sense cRNA probe was synthesized using T7
polymerase. The membrane was hybridized overnight with
digoxigenin labeled sense/antisense riboprobe at 47°C,
washed, incubated with antibody to digoxigenin Fab frag-
ments conjugated with alkaline phosphatase. The bands
were visualized using chromogenic substrate for alkaline
phosphatase.
Fluorescence in situ Hybridization
Male Wistar rats were anesthetized and perfused transcardi-
ally with normal saline followed by buffered paraformal-
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Figure 14 Immunofluorescence localization of P4503A in human brain hippocampus and midbrain using antiserum to P4503A4. (a)
Immunostaining of CA1 pyramidal neurons indicating the presence of P4503A; Bar = 100 m. (b) Higher magnification of the immunos-
tained neurons showing the staining of the axons; Bar = 25 m. (c) Similar section treated with non-immune serum did not show
immunostaining of the CA1 neurons; Bar = 100 m. (d) Immunostaining of reticular neurons in the midbrain indicating the presence of
P4503A was observed; Bar = 100 m. (e) Higher magnification of the reticular neurons; Bar = 25 m. (f) A similar section of midbrain
treated with non-immune serum did not show immunostaining; Bar = 100 m.
dehyde (4%, w/v; 200 ml per rat) prior to the removal of
brain. Different regions from human brain (cortex, cerebel-
lum, hippocampus) were dissected out and fixed in buffered
paraformaldehyde. The tissue was processed for paraffin
embedding and serial sections (8–10 m thick) were cut
under RNase-free conditions. Sections were dewaxed,
hydrated in graded ethanol, acetylated and treated with pro-
teinase-K. The sections were then rinsed in phosphate–buff-
ered saline and dehydrated using graded ethanol. Digoxig-
enin labeled sense (for control sections) and antisense cRNA
www.nature.com/tpj
probes were synthesized from CYP3A1 cDNA using T7 and
SP6 RNA polymerases, respectively. Sections were hybridized
overnight at 42°C with sense or antisense probes. After
hybridization the sections were washed, incubated with
blocking reagent (0.5%, w/v, NEN Life Sciences, USA) and
incubated with antibody to digoxigenin conjugated to horse
radish peroxidase. After washing, the sections were incu-
bated with biotinylated tyramide followed by streptavidin
fluorescein. Finally the sections were washed, dried and
mounted prior to examination under the fluorescence
Metablism of alprazolam by rat and human brain
HV Pai et al
258
microscope.
Immunohistochemistry
Paraffin embedded sections were prepared from rat and
human brain tissue as described above. Sections were
dewaxed and transferred to phosphate buffered saline con-
taining hydrogen peroxide (3%, v/v) to block the endogen-
ous peroxidase reaction. The sections were pressure cooked
in sodium citrate buffer (0.01 M, pH 6) for antigen retrieval.
The sections were blocked with normal goat serum and
incubated with antibody to hepatic P4503A4. Control sec-
tions were incubated with non-immune serum. The sections
were washed, treated with biotinylated anti-rabbit IgG and
incubated with VECTASTAIN–Elite ABC reagent. The color
was developed using diaminobenzidine and hydrogen per-
oxide. The sections were washed, dried and mounted before
examination under the microscope. For immunofluoresc-
ence studies, after incubation with the primary antiserum,
the sections were incubated with anti-rabbit IgG labeled
with peroxidase. After washing, the sections were incubated
with biotinylated tyramide followed by streptavidin fluor-
escein. Finally the sections were washed, dried and mounted
prior to examination under the fluorescence microscope.
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